Status:
COMPLETED
Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients
Lead Sponsor:
Medical University of Vienna
Conditions:
MALT Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate Thalidomide for treatment of disseminated MALT Lymphoma or at relapse following helicobacter pylori (HP) - eradication or chemotherapy or radiation.
Detailed Description
The objectives of this study are to evaluate the effectivity and the safety of thalidomide in patients with disseminated MALT lymphoma or at relapse following HP-eradication, or chemotherapy or radiat...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients with histologically confirmed MALT lymphoma with measurable disease (Stage I-IV)
- With first or greater relapse after HP-eradication, radiation or chemotherapy
- Age \> 18
- Must be able to tolerate therapy and have adequate cardiac, renal and hepatic function
- ECOG status \_\< 2
- Must be capable of understanding the purpose of the study and have given written informed consent
Exclusion
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00373646
Start Date
June 1 2006
End Date
January 1 2009
Last Update
June 18 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Internal Medicine I
Vienna, Austria, 1090